Comparing NeuroOne Medical Technologies (NASDAQ:NMTC) & Fresenius SE & Co. (OTCMKTS:FSNUY)

NeuroOne Medical Technologies (NASDAQ:NMTC) and Fresenius SE & Co. (OTCMKTS:FSNUY) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Risk and Volatility

NeuroOne Medical Technologies has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Fresenius SE & Co. has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500.

Institutional and Insider Ownership

16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 11.8% of NeuroOne Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares NeuroOne Medical Technologies and Fresenius SE & Co.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeuroOne Medical Technologies	-71.50%	-128.12%	-86.34%
Fresenius SE & Co.	6.67%	10.25%	4.87%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for NeuroOne Medical Technologies and Fresenius SE & Co., as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroOne Medical Technologies	1	1	3	0	2.40
Fresenius SE & Co.	0	0	3	0	3.00

NeuroOne Medical Technologies currently has a consensus price target of $7.33, suggesting a potential upside of 464.10%. Given NeuroOne Medical Technologies’ higher probable upside, research analysts plainly believe NeuroOne Medical Technologies is more favorable than Fresenius SE & Co..

Earnings and Valuation

This table compares NeuroOne Medical Technologies and Fresenius SE & Co.”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroOne Medical Technologies	$12.10 million	0.98	-$3.61 million	($0.95)	-1.37
Fresenius SE & Co.	$25.87 billion	1.14	$1.43 billion	$0.79	16.57

Fresenius SE & Co. has higher revenue and earnings than NeuroOne Medical Technologies. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Fresenius SE & Co., indicating that it is currently the more affordable of the two stocks.

Summary

Fresenius SE & Co. beats NeuroOne Medical Technologies on 9 of the 13 factors compared between the two stocks.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.

About Fresenius SE & Co.

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.